Digest Network Come funziona
Network
/
Società
Vi
Non verificato

Virpax Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

15 comunicati stampa

Guarda tutti i comunicati
19/03/2025
Finanza
Scienza
Attrezzature medico-sanitarie
HIV, AIDS e malattie autoimmuni
Sanità
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Virpax Pharmaceuticals Announces Reverse Stock Split
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
18/03/2025
Industria
Veterinaria
Biotecnologia
Management
Farmaceutica
Salute
Sanità
Medicina - Varie
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/03/2025
Industria
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/03/2025
Fiere
Industria
Tecnica
Biotecnologia
Igiene alimentare
Tecnologie Varie
Salute
Farmaceutica
Oncologia
Psichiatria
Scienza
Attrezzature medico-sanitarie
Medicina - Varie
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/02/2025
Scienza
Attrezzature medico-sanitarie
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Analisi di mercato
Industria
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/02/2025
Igiene alimentare
Salute
Medicina - Varie
Sanità
Farmaceutica
Industria
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
31/01/2025
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Eventi
Mercato del lavoro
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/01/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/01/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Finanza
Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
22/11/2024
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Industria
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
Fonte
Virpax Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0